AUG 14·SEC EDGARLow
Booth Andrew purchased $384K of ABCL
Booth Andrew (Chief Financial Officer) purchased 37,200 shares of AbCellera Biologics Inc. (ABCL) at $10.32 ($0.38M total) on 2026-08-14.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ABCL
AbCellera Biologics Inc.
Price · $ABCLvia TradingView
AI sentiment · 7d25 articles
- Bullish
- 12
- Neutral
- 9
- Bearish
- 4
Insider · 30dAll trades →
- Buys
- $865K 2 txs
- Sells
- — 0 txs
Hayden Michael R1× · $481K
10b5-1 share of filings0%
Top stories · $ABCLMore →
AUG 14·SEC EDGAR
Hayden Michael R purchased $481K of ABCL (indirect holdings)
Hayden Michael R purchased 46,387 indirectly-held shares of AbCellera Biologics Inc. (ABCL) at $10.37 ($0.48M total) on 2026-08-12.
AUG 13·SEC EDGAR 8-K
AbCellera Biologics Inc. (ABCL): Entry into a Material Definitive Agreement
AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d20959dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version AbCellera Biologics Inc. 17,435,897 Common Shares 3,076,926 Pre-Funded Warrants UNDERWRITING AGREEMENT August 12, 2026 JEFFERIES LLC J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o
ABCL sentiment & insider activity
Over the past 7 days, alphai's AI scored 25 news stories mentioning ABCL (AbCellera Biologics Inc.). Coverage has skewed bullish: 12 bullish, 9 neutral, and 4 bearish.
Recent ABCL coverage spans corporate actions, insider activity and earnings.
In the last 30 days, ABCL insiders filed 2 SEC Form 4 transactions — 2 purchases ($865K) and no sales. The most active reporter was Hayden Michael R with 1 filing.
What's driving ABCL
This is a disclosed insider buy, but it is not a fundamental catalyst like guidance, trial results, or a deal.
This is a disclosed insider purchase, but it is indirect and not tied to a 10b5-1 plan, so it may modestly support sentiment without changing fundamentals.
The filing discloses a new equity issuance structure, which can pressure near-term valuation via dilution and funding expectations.
A sizable follow-on offering can weigh on the stock via dilution risk, partially offset by balance-sheet extension for clinical programs.
The priced equity raise is likely to pressure near-term valuation via dilution, while providing cash for pipeline and working capital.
alphai scores every news story that mentions ABCL with an AI model for sentiment and relevance, and aggregates insider trades from AbCellera Biologics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ABCL
Score
Booth Andrew purchased $384K of ABCL
Booth Andrew (Chief Financial Officer) purchased 37,200 shares of AbCellera Biologics Inc. (ABCL) at $10.32 ($0.38M total) on 2026-08-14.
1 min readHayden Michael R purchased $481K of ABCL (indirect holdings)
Hayden Michael R purchased 46,387 indirectly-held shares of AbCellera Biologics Inc. (ABCL) at $10.37 ($0.48M total) on 2026-08-12.
1 min readAbCellera Biologics Inc. (ABCL): Entry into a Material Definitive Agreement
AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d20959dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version AbCellera Biologics Inc. 17,435,897 Common Shares 3,076,926 Pre-Funded Warrants UNDERWRITING AGREEMENT August 12, 2026 JEFFERIES LLC J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o
2 min read
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing
Silence Therapeutics plc launched an underwritten U.S. ADS offering of about $150m, priced at $13.50 per ADS for 12,962,963 ADS, targeting gross proceeds of about $175m. AbCellera Biologics commenced a $200m underwritten common share offering. Beyang Therapeutics raised nearly $30m Series A, and Remepy closed a $36m Series A to fund Phase III Hybridopa.
4 min read
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
AbCellera Biologics Inc. (Nasdaq: ABCL) priced an oversubscribed public offering of 17,435,897 common shares at $9.75 each, plus pre-funded warrants for up to 3,076,926 shares at $9.74999 per warrant. Gross proceeds are expected at about $200.0 million. Proceeds will fund pipeline R&D, including ABCL635, and general purposes. Closing expected Aug. 14, 2026.
3 min read
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
AbCellera (ABCL) reported Q2 2026 revenue of $4.1 million versus $17.1 million a year earlier, and a net loss of $55.4 million ($0.18 per share). R&D rose to $46.0 million. Liquidity exceeded $675 million. ABCL635 Phase 2 enrollment and dosing were completed in June, with top-line data expected in August 2026. Jazz and Vertex deals added upfront payments.
7 min readAbCellera Biologics stock analysis: momentum vs. fundamentals
Investing.com says AbCellera Biologics (ABCL) has gained about 197% YTD and trades near $10.15, with analysts citing 53.7% upside and targets up to $30. It notes revenue rose from $28.8M (2024) to $75.1M (2025), but a fair-value model implies it is overvalued versus about $4.82, citing large losses and negative free cash flow.
5 min read
What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)
AbCellera Biologics (NASDAQ:ABCL) began an underwritten public offering of $200 million in common shares and pre-funded warrants. Net proceeds will fund its pipeline, including ABCL635, plus working capital. The company cited Tuesday trial results showing ABCL635 set a new efficacy benchmark for menopausal symptoms. Shares rose about 1.7% to around $9.9.
4 min readAbCellera Unveils $200 Mln Offering Of Shares And Pre-Funded Warrants; Stock Down
AbCellera Biologics (ABCL) said it started an underwritten public offering of $200 million of common shares and pre-funded warrants. The company plans to use net proceeds for continued R&D and clinical progress of ABCL635, plus working capital. It also reported ABCL635 met primary Phase 2 efficacy endpoints for menopausal vasomotor symptoms. ABCL shares fell after the announcement.
4 min read
AbCellera launches $200-million equity offering on heels of strong menopause trial results
AbCellera Biologics (ABCL-Q) launched a US$200 million public offering of common shares and pre-funded warrants, underwritten by Jefferies, J.P. Morgan, Cantor Fitzgerald, UBS Investment Bank and BMO Capital Markets. The deal follows strong ABCL635 hot-flash trial results (92 women), with mean hot-flash reduction 83% vs 33% placebo. Shares rose 35% Monday to $9.76.
6 min read